CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	6 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities
Net income (loss) attributable to Upexi, Inc.	$ 72,164	$ 576,544
Adjustments to reconcile net income from continuing operations to net cash provided by operating activities:
Depreciation and amortization	2,280,021	304,835
Non-cash consideration for sale of Infusionz and select assets, net	(7,094,296)	0
Inventory write-offs	34,328	140,000
Bad debt expense	0	1,000
Amortization of senior security original issue discount	(192,690)	0
Noncontrolling interest	(233,586)	0
Change in deferred tax asset	(15,089)	177,674
Shares issued for services	0	175,000
Shares issued for finder fee	1,770	33,740
Stock based compensation	1,980,173	1,270,553
Changes in assets and liabilities, net of acquired amounts
Accounts receivable	(1,031,715)	113,826
Inventory	6,043,078	(779,808)
Prepaid expenses and other assets	(1,007,505)	(258,054)
Operating lease payable	(86,029)	(49,468)
Accounts payable and accrued liabilities	2,916,158	(699,488)
Deferred revenue	(74,124)	209,833
Net cash provided by operating activities - Continuing Operations	3,592,658	1,216,187
Net cash used in operating activities - Discontinued Operations	0	(826,188)
Net cash provided by operating activities	3,592,658	389,999
Cash flows from investing activities
Acquisition of Lucky Tail	(2,500,000)	0
Acquisition of VitaMedica, Inc., net of cash acquired	(500,000)	(2,074,589)
Acquisition of New England Technology, Inc.	914,611	0
Acquisition of Interative Offers, net of cash acquired	0	(1,854,193)
Proceeds from the sale of Infusionz and selected assets	5,500,000	0
Acquisition of property and equipment	(183,969)	(4,282,430)
Net cash provided by (used in) investing activities - Continuing Operations	3,230,642	(8,211,212)
Net cash (used in) provided by investing activities - Discontinued Operations	0	0
Net cash provided by (used in) investing activities	3,230,642	(8,211,212)
Cash flows from financing activities
Repayment of notes payable	(311,938)	0
Repayment of the senior convertible notes payable	(6,382,989)	(151,004)
Payment on line of credit	(7,201,079)	0
Proceeds from note payable	0	33,967
Proceeds on note payable on building	3,000,000	0
Repayment on note payable on building	(38,939)	0
Proceeds on note payable, related party	1,470,000	0
Net cash used in financing activities - Continuing Operations	(9,464,945)	(117,037)
Net cash (used in) provided by financing activities - Discontinued Operations	0	0
Net cash used in financing activities	(9,464,945)	(117,037)
Net decrease in cash - Continuing Operations	(2,641,645)	(7,112,062)
Net decrease in cash - Discontinued Operations	0	(826,188)
Cash, beginning of period	7,149,806	14,534,211
Cash, end of period	4,508,161	6,595,961
Supplemental cash flow disclosures
Interest paid	0	0
Income tax paid	0	0
Non-cash financing activities
Issuance of common stock for acquisition of Infusionz	0	1,764,876
Issuance of common stock for acquisition of VitaMedica	0	482,000
Issuance of debt for acquisition of VitaMedica	0	1,000,000
Liabilities assumed from acquisition of E-Core	(7,712,168)	0
Non-cash consideration received from Bloomios for the sale of Infusionz	18,000,000	0
Assets available for sale	6,446,210	6,786,289
Liabilities assumed from acquisition of VitaMedica	0	$ (309,574)
Issuance of stock for acquisition of Interactive		4,000,000
Liabilities assumed from acquisition of Interactive	$ 0	$ (1,099,993)